chr2-47416398-C-G
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 6P and 1B. PM5PP3_StrongBP6
The NM_000251.3(MSH2):c.1045C>G(p.Pro349Ala) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000477 in 1,613,108 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. P349L) has been classified as Pathogenic.
Frequency
Consequence
NM_000251.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MSH2 | NM_000251.3 | c.1045C>G | p.Pro349Ala | missense_variant | 6/16 | ENST00000233146.7 | NP_000242.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MSH2 | ENST00000233146.7 | c.1045C>G | p.Pro349Ala | missense_variant | 6/16 | 1 | NM_000251.3 | ENSP00000233146.2 |
Frequencies
GnomAD3 genomes AF: 0.0000657 AC: 10AN: 152120Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000915 AC: 23AN: 251434Hom.: 0 AF XY: 0.0000883 AC XY: 12AN XY: 135890
GnomAD4 exome AF: 0.0000459 AC: 67AN: 1460988Hom.: 0 Cov.: 30 AF XY: 0.0000509 AC XY: 37AN XY: 726870
GnomAD4 genome AF: 0.0000657 AC: 10AN: 152120Hom.: 0 Cov.: 32 AF XY: 0.0000808 AC XY: 6AN XY: 74292
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:2Benign:2
Uncertain significance, no assertion criteria provided | clinical testing | True Health Diagnostics | Aug 11, 2017 | - - |
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Mar 16, 2022 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Aug 09, 2022 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 10, 2020 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
not specified Uncertain:1Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 11, 2023 | Variant summary: MSH2 c.1045C>G (p.Pro349Ala) results in a non-conservative amino acid change located in the core domain (IPR007696) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 9.1e-05 in 251434 control chromosomes, predominantly at a frequency of 0.00035 within the Latino subpopulation in the gnomAD database. This frequency is not significantly higher than estimated for a pathogenic variant in MSH2 causing Hereditary Nonpolyposis Colorectal Cancer (9.1e-05 vs 0.00057), allowing no conclusion about variant significance. The variant, c.1045C>G, has been reported in the literature in individuals affected with colorectal cancer / (suspected) Lynch syndrome (Hansen_2017, Akcay_2020, Ferrer-Avargues_2021) and with other tumor phenotypes, which were mostly outside of the Lynch syndrome tumor spectrum (e.g. Rubio-Del-Campo_2008, Cragun_2014, Landa_2016, Jalkh_2017, Zidan_2017, Dorling_2021), but the variant was also found in healthy controls (e.g. Dorling_2021). In addition, in one of the reported CRC cases a co-occurrence with other pathogenic variant has been reported (MSH2 c.223_224del (p.Leu75AlafsTer), Ferrer-Avargues_2021), providing supporting evidence for a benign role. Multiple publications reported experimental evidence evaluating an impact on protein function, and all of them showed no damaging effect for this variant (Houlleberghs_2016, Bouvet_2019, Jia_2021). Of note, several other missense variants affecting the same residue (e.g. P349L and P349R) were found to be deleterious in these assays (Houlleberghs_2016, Jia_2021), suggesting that although P349 may be critical for protein function, the effect of missense variants at this residue strongly depends on the specific amino acid substitution. The following publications have been ascertained in the context of this evaluation (PMID: 32658311, 25637381, 30998989, 24506336, 33471991, 33630411, 28195393, 26951660, 28202063, 33357406, 24763289, 26878173, 31391288, 28640387, 18325052, 31297992, 28828701, 35264596, 35245693, 36845387). Twelve submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as VUS (n=9) and likely benign (n=3). Based on the evidence outlined above, the variant was classified as likely benign. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Aug 15, 2023 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | May 13, 2020 | The p.Pro349Ala variant in MSH2 is classified as likely benign because it has been identified in 0.08% (8/10366) of Ashkenazi Jewish chromosomes by gnomAD (http://gnomad.broadinstitute.org). ACMG/AMP Criteria applied: BS1. - |
Lynch syndrome 1 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | May 28, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
not provided Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Dec 22, 2023 | The MSH2 c.1045C>G (p.Pro349Ala) variant has been reported in the published literature in individuals affected with colorectal cancer (PMIDs: 28195393 (2017), 28640387 (2017), 32658311 (2021), 33630411 (2021)), breast cancer (PMIDs: 28202063 (2017), 30306255 (2018), 34371384 (2021), 35245693 (2022), 35264596 (2022), 35534704 (2022)), and cervical cancer (PMID: 24506336 (2014)). This variant was also reported to occur with a pathogenic variant in the same MSH2 gene (PMID: 33630411 (2021)) or the BRCA1 gene (PMID: 28202063 (2017)), suggesting this variant may not be the primary cause of disease. Functional studies predicted the variant to be neutral using indirect cell survival assays of MMR function (PMIDs: 26951660 (2016), 30998989 (2019), 33357406 (2021)), however, different amino acid changes at the same codon, p.Pro349Leu and p.Pro349Arg, showed defective MMR function and further research is needed. The frequency of this variant in the general population, 0.00077 (8/10366 chromosomes in Ashkenazi Jewish subpopulation (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is higher than would generally be expected for pathogenic variants in this gene. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Sep 22, 2021 | In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect This variant is associated with the following publications: (PMID: 30998989, 29887214, 18325052, 31297992, 30306255, 28873162, 17720936, 17531815, 21239990, 18951462, 15342696, 28640387, 28828701, 26951660, 28301460, 28584132, 26878173, 27720647, 28195393, 28202063, 24506336, 22949387, 26333163, 25203624, 25637381, 24763289) - |
Hereditary nonpolyposis colon cancer Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | University of Washington Department of Laboratory Medicine, University of Washington | Jan 05, 2021 | ClinVar contains an entry for this variant (ID:90512) which has conflicting classifications. Based on data in gnomAD, the frequency in the Latino population and Ashkenazi Jewish population is higher than expected for a pathogenic MSH2 variant. In a Lebanese family, the variant has been observed to co-occur with a pathogenic variant that could explain the patient disease phenotype (PMID 28202063). - |
Papillary renal cell carcinoma type 1 Uncertain:1
Uncertain significance, no assertion criteria provided | research | CSER _CC_NCGL, University of Washington | Jun 01, 2014 | - - |
Muir-Torré syndrome;C2936783:Lynch syndrome 1;C5399763:Mismatch repair cancer syndrome 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Hereditary nonpolyposis colorectal neoplasms Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Hereditary breast ovarian cancer syndrome Benign:1
Benign, criteria provided, single submitter | curation | German Consortium for Hereditary Breast and Ovarian Cancer, University Hospital Cologne | Sep 10, 2024 | According to the ClinGen InSiGHT ACMG MSH2 v1.0.0 criteria we chose these criteria: PP3 (medium pathogenic): prior Propability: 0,87: mod, BS1 (strong benign): GnomAD v4 Grpmax filtering allele frequency = 0.0002341 (thus, ≥ 0.0001 and < 0.001 (0.01-0.1%)), BS3 (strong benign): PMID: 33357406 / Jia et. al (2021): LOF Score of -2.77 in functional assay. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at